Novel actionable ROS1::GIT2 fusion in non-Langerhans cell histiocytosis with central nervous system involvement

被引：0
|
作者：
Bedics, Gabor [1 ,2 ]
Csoka, Monika [3 ]
Reiniger, Lilla [1 ]
Varga, Edit [3 ]
Liptai, Zoltan [3 ]
Papp, Gergo [1 ]
Beko, Anna [1 ,2 ]
Cervi, Catherine [3 ]
Bodor, Csaba [1 ,2 ]
Scheich, Balint [1 ]
机构：
[1] Semmelweis Univ, Dept Pathol & Expt Canc Res, Ulloi Ut 26, H-1085 Budapest, Hungary
[2] Semmelweis Univ, Dept Pathol & Expt Canc Res, HCEMM SU Mol Oncohematol Res Grp, Ulloi Ut 26, H-1085 Budapest, Hungary
[3] Semmelweis Univ, Dept Pediat 2, Tuzolto U 7-9, H-1094 Budapest, Hungary
来源：
ACTA NEUROPATHOLOGICA | 2023年 / 145卷 / 01期
基金：
欧盟地平线“2020”;
关键词：
D O I：
10.1007/s00401-022-02520-6
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：153 / 156
页数：4
相关论文
共 38 条
  • [21] Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
    Drilon, Alexander
    Siena, Salvatore
    Dziadziuszko, Rafal
    Barlesi, Fabrice
    Krebs, Matthew G.
    Shaw, Alice T.
    de Braud, Filippo
    Rolfo, Christian
    Ahn, Myung-Ju
    Wolf, Juergen
    Seto, Takashi
    Cho, Byoung Chul
    Patel, Manish R.
    Chiu, Chao-Hua
    John, Thomas
    Goto, Koichi
    Karapetis, Christos S.
    Arkenau, Hendrick-Tobias
    Kim, Sang-We
    Ohe, Yuichiro
    Li, Yu-Chung
    Chae, Young K.
    Chung, Christine H.
    Otterson, Gregory A.
    Murakami, Haruyasu
    Lin, Chia-Chi
    Tan, Daniel S. W.
    Prenen, Hans
    Riehl, Todd
    Chow-Maneval, Edna
    Simmons, Brian
    Cui, Na
    Johnson, Ann
    Eng, Susan
    Wilson, Timothy R.
    Doebele, Robert C.
    LANCET ONCOLOGY, 2020, 21 (02): : 261 - 270
  • [22] Repotrectinib in patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Update from the pivotal phase 1/2 TRIDENT-1 trial
    Lin, Jessica J.
    Cho, Byoung Chul
    Camidge, D. Ross
    Kim, Sang-We
    Solomon, Benjamin
    Dziadziuszko, Rafal
    Besse, Benjamin
    Goto, Koichi
    de langen, Adrianus Johannes
    Wolf, Jurgen
    Lee, Ki Hyeong
    Popat, Sanjay
    Springfeld, Christoph
    Nagasaka, Misako
    Felip, Enriqueta
    Yang, Nong
    Lu, Shun
    Kao, Steven
    Velcheti, Vamsidhar
    Cheema, Parneet
    Stopatschinskaja, Shanna
    Mehta, Minal
    Trone, Denise
    Ades, Felipe
    Calvet, Christophe Y.
    Drilon, Alexander
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [23] Detecting ALK, ROS1 and RET Fusion Genes in Advanced Non-Small Cell Lung Cancer (NSCLC) Using a Novel Multiplexed NCounter-Based Assay
    Reguart, Noemi
    Gimenez-Capitan, Ana
    Angel Molina, Miguel
    Galvan, Patricia
    Pare, Laia
    Viteri, Santiago
    Teixido, Cristina
    Rodriguez, Sonia
    Castellvi, Josep
    Aldeguer, Erika
    Vinolas, Nuria
    Rosell, Rafael
    Prat, Aleix
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S341 - S341
  • [24] Detection of ALK, ROS1 and RET fusion transcripts in FFPE samples of non-small cell lung cancer patients using a novel RT-PCR based assay
    Denis, Marc G.
    Vallee, Audrey
    Sagan, Christine
    Herbreteau, Guillaume
    Charpentier, Sandrine
    Rajamani, Jaya
    Lee, Michael
    Ordinario, Ellen
    CANCER RESEARCH, 2022, 82 (12)
  • [25] Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials (vol 21, pg 261, 2020)
    Drilon, A.
    Siena, S.
    Dziadziuszko, R.
    LANCET ONCOLOGY, 2020, 21 (02): : E70 - E70
  • [26] Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials (vol 21, pg 261, 2020)
    Drilon, A.
    Siena, S.
    Dziadziuszko, R.
    LANCET ONCOLOGY, 2020, 21 (07): : E341 - E341
  • [27] Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study
    Barlesi, F.
    Wolf, J.
    Ahn, M-J.
    Doebele, R. C.
    Paz-Ares, L.
    Rolfo, C.
    Siena, S.
    Seto, T.
    Ohe, Y.
    Ou, S. H. I.
    Krebs, M. G.
    Kapre, A.
    Piault-Louis, E.
    McCallum, S.
    Osborne, S.
    Aziez, A.
    Drilon, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1391 - S1392
  • [28] The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib
    Patil, Tejas
    Smith, Derek E.
    Bunn, Paul A.
    Aisner, Dara L.
    Le, Anh T.
    Hancock, Mark
    Purcell, William T.
    Bowles, Daniel W.
    Camidge, D. Ross
    Doebele, Robert C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (11) : 1717 - 1726
  • [29] Detection of ALK and ROS1 fusion transcripts in FFPE samples of non-small cell lung cancer patients using a novel RT-PCR based assay and targeted RNA sequencing.
    Denis, Marc G.
    Vallee, Audrey
    Sagan, Christine
    Herbreteau, Guillaume
    Theoleyre, Sandrine
    Rajamani, Jaya
    Lee, Michael
    Ordinario, Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
    Barlesi, F.
    Drilon, A.
    De Braud, F.
    Cho, B. C.
    Ahn, M. J.
    Siena, S.
    Krebs, M. G.
    Lin, C. C.
    John, T.
    Tan, D. S. W.
    Seto, T.
    Dziadziuszko, R.
    Arkenau, H-T.
    Rolfo, C.
    Wolf, J.
    Ye, C.
    Riehl, T.
    Eng, S.
    Doebele, R. C.
    ANNALS OF ONCOLOGY, 2019, 30
1234